Canada’s Ongoing Struggle For Access To Natural Psilocybin As A Therapeutic Nabs Business Support
Ontario-based Red Light Holland Corp. (OTCQB: TRUFF) has committed to becoming an aligned supporter and advocate with the non-profit TheraPsil.
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications with the United S
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022.
The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023.
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder.
How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out
Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its natural psilocybin standardized extract with its proprietary MDMA drug candidate in healthy therapists.
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral,
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Specialty ketamine company PharmaTher Holdings Ltd.
Australia’s Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions
As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the